Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIGA-2339 in Chronic Hepatitis B Virus Infection
NCT07024641Phase 1Recruiting
- Sponsor
- GigaGen Inc.
- Start
- Nov 2024
- Primary completion
- Nov 2028
- Modality
- Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of GIGA-2339 in chronic hepatitis B virus infection (CHB) (2 arms), sponsored by GigaGen Inc. Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). Started Nov 2024; status: recruiting.
02
Drugs
GIGA-2339
03
Conditions
chronic hepatitis B virus infection (CHB)
Beyond the preview
Go deeper on NCT07024641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024641.